TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Summary

The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus half-dose donafenib (a kind of anti-angiogenesis agents) in advanced hepatocellular carcinoma (BCLC-C Stage) accompanied by tumor thrombosis-associated portal hypertension.

Timeline

Start

2024-10-08

Primary completion

2026-05-31

Completion

2026-12-31

Drugs

Indications